Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 47

1.

Is it time to incorporate surgery in the treatment of stage IV non-small cell lung cancer?

Hendriks LEL, Dingemans AC.

Lung Cancer. 2019 Jan 30. pii: S0169-5002(19)30297-1. doi: 10.1016/j.lungcan.2019.01.011. [Epub ahead of print] No abstract available.

PMID:
30738574
2.

Induction of Peripheral Effector CD8 T-cell Proliferation by Combination of Paclitaxel, Carboplatin, and Bevacizumab in Non-small Cell Lung Cancer Patients.

de Goeje PL, Poncin M, Bezemer K, Kaijen-Lambers MEH, Groen HJM, Smit EF, Dingemans AC, Kunert A, Hendriks RW, Aerts JGJV.

Clin Cancer Res. 2019 Jan 14. doi: 10.1158/1078-0432.CCR-18-2243. [Epub ahead of print]

PMID:
30642911
3.

Is Concurrent Chemoradiotherapy Also the Best Treatment for Elderly Patients with Limited-Stage Small Cell Lung Cancer? - What the CONVERT Data Can Tell Us.

van Loon J, Dingemans AC.

J Thorac Oncol. 2019 Jan;14(1):13-15. doi: 10.1016/j.jtho.2018.11.005. No abstract available.

PMID:
30579544
4.

Is the sum of positive neuroendocrine immunohistochemical stains useful for diagnosis of large cell neuroendocrine carcinoma (LCNEC) on biopsy specimens?

Derks JL, Dingemans AC, van Suylen RJ, den Bakker MA, Damhuis RAM, van den Broek EC, Speel EJ, Thunnissen E.

Histopathology. 2019 Mar;74(4):555-566. doi: 10.1111/his.13800. Epub 2019 Jan 24.

PMID:
30485478
5.

Editorial: Central Nervous System Metastases in Lung Cancer Patients: From Prevention to Diagnosis and Treatment.

Hendriks LEL, Subramaniam DS, Dingemans AC.

Front Oncol. 2018 Nov 6;8:511. doi: 10.3389/fonc.2018.00511. eCollection 2018. No abstract available.

6.

Applicability of a prognostic CT-based radiomic signature model trained on stage I-III non-small cell lung cancer in stage IV non-small cell lung cancer.

de Jong EEC, van Elmpt W, Rizzo S, Colarieti A, Spitaleri G, Leijenaar RTH, Jochems A, Hendriks LEL, Troost EGC, Reymen B, Dingemans AC, Lambin P.

Lung Cancer. 2018 Oct;124:6-11. doi: 10.1016/j.lungcan.2018.07.023. Epub 2018 Jul 20.

7.

Progression-Free Survival and Overall Survival Beyond 5 Years of NSCLC Patients With Synchronous Oligometastases Treated in a Prospective Phase II Trial (NCT 01282450).

De Ruysscher D, Wanders R, Hendriks LE, van Baardwijk A, Reymen B, Houben R, Bootsma G, Pitz C, van Eijsden L, Dingemans AC.

J Thorac Oncol. 2018 Dec;13(12):1958-1961. doi: 10.1016/j.jtho.2018.07.098. Epub 2018 Sep 22.

PMID:
30253974
8.

Safety and Efficacy of Bevacizumab Plus Standard-of-Care Treatment Beyond Disease Progression in Patients With Advanced Non-Small Cell Lung Cancer: The AvaALL Randomized Clinical Trial.

Gridelli C, de Castro Carpeno J, Dingemans AC, Griesinger F, Grossi F, Langer C, Ohe Y, Syrigos K, Thatcher N, Das-Gupta A, Truman M, Donica M, Smoljanovic V, Bennouna J.

JAMA Oncol. 2018 Dec 1;4(12):e183486. doi: 10.1001/jamaoncol.2018.3486. Epub 2018 Dec 13.

PMID:
30177994
9.

Brain imaging in early stage non-small cell lung cancer: still a controversial topic?

Schoenmaekers JJAO, Dingemans AC, Hendriks LEL.

J Thorac Dis. 2018 Jul;10(Suppl 18):S2168-S2171. doi: 10.21037/jtd.2018.06.68. No abstract available.

10.

Study Protocol of the NVALT25-ELDAPT Trial: Selecting the Optimal Treatment for Older Patients With Stage III Non-small-cell Lung Cancer.

Driessen EJM, Janssen-Heijnen MLG, Maas HA, Dingemans AC, van Loon JGM.

Clin Lung Cancer. 2018 Nov;19(6):e849-e852. doi: 10.1016/j.cllc.2018.07.003. Epub 2018 Jul 9.

PMID:
30097357
11.

The Prevention of Brain Metastases in Non-Small Cell Lung Cancer by Prophylactic Cranial Irradiation.

Witlox WJA, Ramaekers BLT, Zindler JD, Eekers DBP, van Loon JGM, Hendriks LEL, Dingemans AC, De Ruysscher DKM.

Front Oncol. 2018 Jul 26;8:241. doi: 10.3389/fonc.2018.00241. eCollection 2018. Review.

12.

What you see is (not) what you get: tools for a non-radiologist to evaluate image quality in lung cancer.

de Jong EEC, Hendriks LEL, van Elmpt W, Gietema HA, Hofman PAM, De Ruysscher DKM, Dingemans AC.

Lung Cancer. 2018 Sep;123:112-115. doi: 10.1016/j.lungcan.2018.07.014. Epub 2018 Jul 18.

PMID:
30089580
13.

Invasive Aspergillosis Mimicking Metastatic Lung Cancer.

Vanfleteren MJEGW, Dingemans AC, Surmont VF, Vermaelen KY, Postma AA, Oude Lashof AML, Pitz CCM, Hendriks LEL.

Front Oncol. 2018 Jun 5;8:188. doi: 10.3389/fonc.2018.00188. eCollection 2018.

14.

Association of molecular status and metastatic organs at diagnosis in patients with stage IV non-squamous non-small cell lung cancer.

Kuijpers CCHJ, Hendriks LEL, Derks JL, Dingemans AC, van Lindert ASR, van den Heuvel MM, Damhuis RA, Willems SM.

Lung Cancer. 2018 Jul;121:76-81. doi: 10.1016/j.lungcan.2018.05.006. Epub 2018 May 15.

15.

Prophylactic Cranial Irradiation Versus Observation in Radically Treated Stage III Non-Small-Cell Lung Cancer: A Randomized Phase III NVALT-11/DLCRG-02 Study.

De Ruysscher D, Dingemans AC, Praag J, Belderbos J, Tissing-Tan C, Herder J, Haitjema T, Ubbels F, Lagerwaard F, El Sharouni SY, Stigt JA, Smit E, van Tinteren H, van der Noort V, Groen HJM.

J Clin Oncol. 2018 Aug 10;36(23):2366-2377. doi: 10.1200/JCO.2017.77.5817. Epub 2018 May 22.

PMID:
29787357
16.

A phase I study of nintedanib combined with cisplatin/gemcitabine as first-line therapy for advanced squamous non-small cell lung cancer (LUME-Lung 3).

Forster M, Hackshaw A, De Pas T, Cobo M, Garrido P, Summers Y, Dingemans AC, Flynn M, Schnell D, von Wangenheim U, Loembé AB, Kaiser R, Lee SM.

Lung Cancer. 2018 Jun;120:27-33. doi: 10.1016/j.lungcan.2018.03.007. Epub 2018 Mar 9.

17.

Geriatric Assessment for Older Patients with Non-small Cell Lung Cancer: Daily Practice of Centers Participating in the NVALT25-ELDAPT Trial.

Driessen EJM, van Loon JGM, Maas HA, Dingemans AC, Janssen-Heijnen MLG.

Lung. 2018 Aug;196(4):463-468. doi: 10.1007/s00408-018-0116-8. Epub 2018 Apr 12.

PMID:
29651598
18.

Diversity of brain metastases screening and management in non-small cell lung cancer in Europe: Results of the European Organisation for Research and Treatment of Cancer Lung Cancer Group survey.

Levy A, Faivre-Finn C, Hasan B, De Maio E, Berghoff AS, Girard N, Greillier L, Lantuéjoul S, O'Brien M, Reck M, Dingemans AC, Novello S, Berghmans T, Besse B, Hendriks L; Young Investigators EORTC Lung Cancer Group (YI EORTC LCG).

Eur J Cancer. 2018 Apr;93:37-46. doi: 10.1016/j.ejca.2018.01.067. Epub 2018 Feb 21.

PMID:
29477100
19.

New Insights into the Molecular Characteristics of Pulmonary Carcinoids and Large Cell Neuroendocrine Carcinomas, and the Impact on Their Clinical Management.

Derks JL, Leblay N, Lantuejoul S, Dingemans AC, Speel EM, Fernandez-Cuesta L.

J Thorac Oncol. 2018 Jun;13(6):752-766. doi: 10.1016/j.jtho.2018.02.002. Epub 2018 Feb 14. Review. Erratum in: J Thorac Oncol. 2018 Aug;13(8):1229.

PMID:
29454048
20.

Exploration of the platelet proteome in patients with early-stage cancer.

Sabrkhany S, Kuijpers MJE, Knol JC, Olde Damink SWM, Dingemans AC, Verheul HM, Piersma SR, Pham TV, Griffioen AW, Oude Egbrink MGA, Jimenez CR.

J Proteomics. 2018 Apr 15;177:65-74. doi: 10.1016/j.jprot.2018.02.011. Epub 2018 Feb 10.

21.

Current perspective: Osimertinib-induced QT prolongation: new drugs with new side-effects need careful patient monitoring.

Schiefer M, Hendriks LEL, Dinh T, Lalji U, Dingemans AC.

Eur J Cancer. 2018 Mar;91:92-98. doi: 10.1016/j.ejca.2017.12.011. Review.

PMID:
29413968
22.

Patterns of treatment and survival among older patients with stage III non-small cell lung cancer.

Driessen EJM, Schulkes KJG, Dingemans AC, van Loon JGM, Hamaker ME, Aarts MJ, Janssen-Heijnen MLG.

Lung Cancer. 2018 Feb;116:55-61. doi: 10.1016/j.lungcan.2017.12.013. Epub 2017 Dec 20.

PMID:
29413051
23.

The effect of itraconazole and rifampicin on the pharmacokinetics of osimertinib.

Vishwanathan K, Dickinson PA, So K, Thomas K, Chen YM, De Castro Carpeño J, Dingemans AC, Kim HR, Kim JH, Krebs MG, Chih-Hsin Yang J, Bui K, Weilert D, Harvey RD.

Br J Clin Pharmacol. 2018 Jun;84(6):1156-1169. doi: 10.1111/bcp.13534. Epub 2018 Mar 23.

PMID:
29381826
24.

Prevalence and clinical association of gene mutations through multiplex mutation testing in patients with NSCLC: results from the ETOP Lungscape Project.

Kerr KM, Dafni U, Schulze K, Thunnissen E, Bubendorf L, Hager H, Finn S, Biernat W, Vliegen L, Losa JH, Marchetti A, Cheney R, Warth A, Speel EJ, Blackhall F, Monkhorst K, Jantus Lewintre E, Tischler V, Clark C, Bertran-Alamillo J, Meldgaard P, Gately K, Wrona A, Vandenberghe P, Felip E, De Luca G, Savic S, Muley T, Smit EF, Dingemans AC, Priest L, Baas P, Camps C, Weder W, Polydoropoulou V, Geiger TR, Kammler R, Sumiyoshi T, Molina MA, Shames DS, Stahel RA, Peters S; ETOP Lungscape Consortium.

Ann Oncol. 2018 Jan 1;29(1):200-208. doi: 10.1093/annonc/mdx629.

PMID:
29186353
25.

Cumulative incidence rates for CNS and non-CNS progression in two phase II studies of alectinib in ALK-positive NSCLC.

Gadgeel S, Shaw AT, Barlesi F, Crinò L, Yang JC, Dingemans AC, Kim DW, de Marinis F, Schulz M, Liu S, Gupta R, Kotb A, Ou SI.

Br J Cancer. 2018 Jan;118(1):38-42. doi: 10.1038/bjc.2017.395. Epub 2017 Nov 16.

26.

Why we should improve current practice of diagnosing and treating pulmonary large cell neuroendocrine carcinomas in patients with advanced disease.

Derks J, van Suylen RJ, Thunnissen E, den Bakker M, Groen H, Smit E, Damhuis R, van den Broek E, Speel EJ, Dingemans AC.

Eur Respir J. 2017 Oct 26;50(4). pii: 1701658. doi: 10.1183/13993003.01658-2017. Print 2017 Oct. No abstract available.

PMID:
29074548
27.

Molecular Subtypes of Pulmonary Large-cell Neuroendocrine Carcinoma Predict Chemotherapy Treatment Outcome.

Derks JL, Leblay N, Thunnissen E, van Suylen RJ, den Bakker M, Groen HJM, Smit EF, Damhuis R, van den Broek EC, Charbrier A, Foll M, McKay JD, Fernandez-Cuesta L, Speel EM, Dingemans AC; PALGA-Group.

Clin Cancer Res. 2018 Jan 1;24(1):33-42. doi: 10.1158/1078-0432.CCR-17-1921. Epub 2017 Oct 24.

28.

Management of Progressive Pulmonary Nodules Found during and outside of CT Lung Cancer Screening Studies.

Meyer M, Vliegenthart R, Henzler T, Buergy D, Giordano FA, Kostrzewa M, Rathmann N, Brustugun OT, Crino L, Dingemans AC, Dusmet M, Fennell D, Grunenwald D, Huber RM, Moniuszko M, Mornex F, Papotti M, Pilz L, Senan S, Syrigos K, Pérol M, Gray JE, Schabel C, van Meerbeeck JP, van Zandwijk N, Zhou CC, Manegold C, Voigt W, Roessner ED.

J Thorac Oncol. 2017 Dec;12(12):1755-1765. doi: 10.1016/j.jtho.2017.09.1956. Epub 2017 Sep 27. Review.

29.

Quality assessment of positron emission tomography scans: recommendations for future multicentre trials.

de Jong EEC, van Elmpt W, Hoekstra OS, Groen HJM, Smit EF, Boellaard R, Lambin P, Dingemans AC.

Acta Oncol. 2017 Nov;56(11):1459-1464. doi: 10.1080/0284186X.2017.1346824. Epub 2017 Aug 22.

PMID:
28830270
30.

Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of Alectinib in ALK-positive Non-Small Cell Lung Cancer.

Yang JC, Ou SI, De Petris L, Gadgeel S, Gandhi L, Kim DW, Barlesi F, Govindan R, Dingemans AC, Crino L, Lena H, Popat S, Ahn JS, Dansin E, Golding S, Bordogna W, Balas B, Morcos PN, Zeaiter A, Shaw AT.

J Thorac Oncol. 2017 Oct;12(10):1552-1560. doi: 10.1016/j.jtho.2017.06.070. Epub 2017 Jul 6.

31.

Efficacy of alectinib in central nervous system metastases in crizotinib-resistant ALK-positive non-small-cell lung cancer: Comparison of RECIST 1.1 and RANO-HGG criteria.

Gandhi L, Ou SI, Shaw AT, Barlesi F, Dingemans AC, Kim DW, Camidge DR, Hughes BGM, Yang JC, de Castro J, Crino L, Léna H, Do P, Golding S, Bordogna W, Zeaiter A, Kotb A, Gadgeel S.

Eur J Cancer. 2017 Sep;82:27-33. doi: 10.1016/j.ejca.2017.05.019. Epub 2017 Jul 10.

PMID:
28646771
32.

Chemotherapy for pulmonary large cell neuroendocrine carcinomas: does the regimen matter?

Derks JL, van Suylen RJ, Thunnissen E, den Bakker MA, Groen HJ, Smit EF, Damhuis RA, van den Broek EC, Speel EM, Dingemans AC; PALGA group.

Eur Respir J. 2017 Jun 1;49(6). pii: 1601838. doi: 10.1183/13993003.01838-2016. Print 2017 Jun.

33.

A combination of platelet features allows detection of early-stage cancer.

Sabrkhany S, Kuijpers MJE, van Kuijk SMJ, Sanders L, Pineda S, Olde Damink SWM, Dingemans AC, Griffioen AW, Oude Egbrink MGA.

Eur J Cancer. 2017 Jul;80:5-13. doi: 10.1016/j.ejca.2017.04.010. Epub 2017 May 17.

PMID:
28527393
34.

Heat shock protein antagonists in early stage clinical trials for NSCLC.

Hendriks LEL, Dingemans AC.

Expert Opin Investig Drugs. 2017 May;26(5):541-550. doi: 10.1080/13543784.2017.1302428. Epub 2017 Mar 8. Review.

PMID:
28274158
35.

Thoracic oncology HERMES: European curriculum recommendations for training in thoracic oncology.

Gamarra F, Noël JL, Brunelli A, Dingemans AC, Felip E, Gaga M, Grigoriu BD, Hardavella G, Huber RM, Janes S, Massard G, Putora PM, Sculier JP, Schnabel PA, Ramella S, Van Raemdonck D, Meert AP.

Breathe (Sheff). 2016 Sep;12(3):249-255. doi: 10.1183/20734735.009116. Review.

36.

Dichotomous ALK-IHC Is a Better Predictor for ALK Inhibition Outcome than Traditional ALK-FISH in Advanced Non-Small Cell Lung Cancer.

van der Wekken AJ, Pelgrim R, 't Hart N, Werner N, Mastik MF, Hendriks L, van der Heijden EHFM, Looijen-Salamon M, de Langen AJ, Staal-van den Brekel J, Riemersma S, van den Borne BE, Speel EJM, Dingemans AC, Hiltermann TJN, van den Berg A, Timens W, Schuuring E, Groen HJM.

Clin Cancer Res. 2017 Aug 1;23(15):4251-4258. doi: 10.1158/1078-0432.CCR-16-1631. Epub 2017 Feb 9.

37.

Management of stage I and II nonsmall cell lung cancer.

McDonald F, De Waele M, Hendriks LE, Faivre-Finn C, Dingemans AC, Van Schil PE.

Eur Respir J. 2017 Jan 3;49(1). pii: 1600764. doi: 10.1183/13993003.00764-2016. Print 2017 Jan. Review.

38.

PET imaging of zirconium-89 labelled cetuximab: A phase I trial in patients with head and neck and lung cancer.

van Loon J, Even AJG, Aerts HJWL, Öllers M, Hoebers F, van Elmpt W, Dubois L, Dingemans AC, Lalisang RI, Kempers P, Brans B, Winnepenninckx V, Speel EJ, Thunnissen E, Smits KM, Boellaard R, Vugts DJ, De Ruysscher D, Lambin P.

Radiother Oncol. 2017 Feb;122(2):267-273. doi: 10.1016/j.radonc.2016.11.020. Epub 2016 Dec 21.

PMID:
28012793
39.

Is selective nodal irradiation in non-small cell lung cancer still safe when using IMRT? Results of a prospective cohort study.

Martinussen HM, Reymen B, Wanders R, Troost EG, Dingemans AC, Öllers M, Houben R, De Ruysscher D, Lambin P, van Baardwijk A.

Radiother Oncol. 2016 Nov;121(2):322-327. doi: 10.1016/j.radonc.2016.10.001. Epub 2016 Nov 21.

PMID:
27884510
40.

Development of symptomatic brain metastases after chemoradiotherapy for stage III non-small cell lung cancer: Does the type of chemotherapy regimen matter?

Hendriks LE, Brouns AJ, Amini M, Uyterlinde W, Wijsman R, Bussink J, Biesma B, Oei SB, Stigt JA, Bootsma GP, Belderbos JS, De Ruysscher DK, Van den Heuvel MM, Dingemans AC.

Lung Cancer. 2016 Nov;101:68-75. doi: 10.1016/j.lungcan.2016.09.008. Epub 2016 Sep 9.

41.

Stage III Non-Small Cell Lung Cancer in the elderly: Patient characteristics predictive for tolerance and survival of chemoradiation in daily clinical practice.

Driessen EJ, Bootsma GP, Hendriks LE, van den Berkmortel FW, Bogaarts BA, van Loon JG, Dingemans AC, Janssen-Heijnen ML.

Radiother Oncol. 2016 Oct;121(1):26-31. doi: 10.1016/j.radonc.2016.07.025. Epub 2016 Aug 10.

PMID:
27522577
42.

The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC.

Manegold C, Dingemans AC, Gray JE, Nakagawa K, Nicolson M, Peters S, Reck M, Wu YL, Brustugun OT, Crinò L, Felip E, Fennell D, Garrido P, Huber RM, Marabelle A, Moniuszko M, Mornex F, Novello S, Papotti M, Pérol M, Smit EF, Syrigos K, van Meerbeeck JP, van Zandwijk N, Chih-Hsin Yang J, Zhou C, Vokes E.

J Thorac Oncol. 2017 Feb;12(2):194-207. doi: 10.1016/j.jtho.2016.10.003. Epub 2016 Oct 8. Review.

43.

[18F]FDG PET/CT-based response assessment of stage IV non-small cell lung cancer treated with paclitaxel-carboplatin-bevacizumab with or without nitroglycerin patches.

de Jong EE, van Elmpt W, Leijenaar RT, Hoekstra OS, Groen HJ, Smit EF, Boellaard R, van der Noort V, Troost EG, Lambin P, Dingemans AC.

Eur J Nucl Med Mol Imaging. 2017 Jan;44(1):8-16. Epub 2016 Sep 6.

44.

Differentiating head and neck carcinoma from lung carcinoma with an electronic nose: a proof of concept study.

van Hooren MR, Leunis N, Brandsma DS, Dingemans AC, Kremer B, Kross KW.

Eur Arch Otorhinolaryngol. 2016 Nov;273(11):3897-3903. Epub 2016 Apr 16.

45.

Immunoglobulin-like transcript 3 is expressed by myeloid-derived suppressor cells and correlates with survival in patients with non-small cell lung cancer.

de Goeje PL, Bezemer K, Heuvers ME, Dingemans AC, Groen HJ, Smit EF, Hoogsteden HC, Hendriks RW, Aerts JG, Hegmans JP.

Oncoimmunology. 2015 Mar 19;4(7):e1014242. eCollection 2015 Jul.

46.

Pre-cachexia in patients with stages I-III non-small cell lung cancer: systemic inflammation and functional impairment without activation of skeletal muscle ubiquitin proteasome system.

Op den Kamp CM, Langen RC, Minnaard R, Kelders MC, Snepvangers FJ, Hesselink MK, Dingemans AC, Schols AM.

Lung Cancer. 2012 Apr;76(1):112-7. doi: 10.1016/j.lungcan.2011.09.012. Epub 2011 Oct 20.

47.

Topoisomerase IIalpha and other drug resistance markers in advanced non-small cell lung cancer.

Dingemans AC, van Ark-Otte J, Span S, Scagliotti GV, van der Valk P, Postmus PE, Giaccone G.

Lung Cancer. 2001 May;32(2):117-28.

PMID:
11325482

Supplemental Content

Loading ...
Support Center